Funder: National Institutes of Health

Due Dates: June 17, 2025 (New) | July 17, 2025 (Renewal/Resubmission/Revision) | October 17, 2025 (New) | November 18, 2025 (Renewal/Resubmission/Revision) | February 18, 2026 (New) | March 17, 2026 (Renewal/Resubmission/Revision) | June 17, 2026 (New) | July 17, 2026 (Renewal/Resubmission/Revision) | October 19, 2026 (New) | November 17, 2026 (Renewal/Resubmission/Revision) | May 18, 2025 (Letter of Intent)

Funding Amounts: R61 phase: up to $350,000 direct costs over 2 years (max $225,000/year); R33 phase: up to $500,000 direct costs/year for up to 3 years; total project period up to 5 years.

Summary: Supports phased research (R61/R33) on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD), with a strong emphasis on clinical trials.

Key Information: Highest priority is given to applications proposing clinical trials; transition from R61 to R33 is milestone-dependent and not guaranteed.